Companies: 10,795·Total market cap: $144.5T
Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc.

CRXTQOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$72829
P/E Ratio—
52W High$3.94
52W Low$0.001
SEC Filings

Clarus Therapeutics Holdings, Inc. (CRXTQ) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001817944 · CRXTQ · OTC · as of Jun 10, 2026

Filing snapshot

236
Total Filings
EFFECT
Latest Form
2023-03-06
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001817944 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2022-04-28
Fiscal Year End
Apr 28, 2022
Accession No.
0001193125-22-125177
Primary Document
d213583d10ka.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001817944 · Accession 0001193125-22-125177

Latest Key Filings

10-QQuarterly Report
10-Q
2022-08-19
View 10-Q on SEC
8-KCurrent Report
CURRENT REPORT
2023-03-01Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
EFFECTEFFECT
EFFECT
2023-03-06
View
EFFECTEFFECT
EFFECT
2023-03-06
View
EFFECTEFFECT
EFFECT
2023-03-06
View
EFFECTEFFECT
EFFECT
2023-03-06
View
15-12G15-12G
FORM 15-12G
2023-03-01
View
8-KCurrent Report
CURRENT REPORT
2023-03-01
View
S-8 POSS-8 POS
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8
2023-03-01
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
2023-03-01
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
2023-03-01
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1
2023-03-01
View
POS AMPOS AM
POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1
2023-03-01
View
8-KCurrent Report
CURRENT REPORT
2023-02-22
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2023-02-14
View
8-KCurrent Report
CURRENT REPORT
2023-01-24
View
8-KCurrent Report
CURRENT REPORT
2022-12-22
View
Showing 1–15 of 214 filingsForm 4 / 144 hidden· 236 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001817944  |  Exchange: OTC · Healthcare

Clarus Therapeutics Holdings, Inc. (OTC: CRXTQ) has submitted 236 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001817944, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Clarus Therapeutics Holdings, Inc.'s most comprehensive regulatory disclosure. The most recent Clarus Therapeutics Holdings, Inc. 10-K was filed on 2022-04-28 for fiscal year ending 2022. Historical CRXTQ 10-K annual reports are available from 2020 through 2022.

Investors researching Clarus Therapeutics Holdings, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
POTN SEC Filings →PRED SEC Filings →NVTAQ SEC Filings →NXNN SEC Filings →HCLC SEC Filings →UNRV SEC Filings →SLHGF SEC Filings →OTRKQ SEC Filings →
→ CRXTQ Financials→ CRXTQ Earnings→ CRXTQ Insider Trades

Frequently Asked Questions

CRXTQ SEC Filings · 8 questions

Clarus Therapeutics Holdings, Inc. (CRXTQ) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 236 filings and access original documents at no cost. Clarus Therapeutics Holdings, Inc.'s CIK is 0001817944.

CRXTQ SEC filingsClarus Therapeutics Holdings, Inc. SEC documentsfind CRXTQ 10-K